Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Caloz | M | 72 | 17 years | |
| John Weber | M | 74 | 14 years | |
| Elise Brownell | M | - | 10 years | |
| Felix Kratz | M | - | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Kriegsman | M | 82 | 20 years | |
| Louis J. Ignarro | M | 83 | 20 years | |
| Dennis Fenton | M | 72 | 27 years | |
| Elliott L. Fineman | M | - |
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 20 years |
| Cheryl Cohen | F | 58 | 1 years | |
| Anita J. Chawla | M | 65 | 2 years | |
| Eric Jay Selter | M | 66 | 2 years | |
| Craig Eagle | M | 57 | 7 years | |
| Max E. Link | M | 84 | 18 years | |
| Iain Ross | M | 71 | 1 years | |
| Ronald Spair | M | 58 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 2 years |
| James Manuso | M | 75 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 10 years |
| George B. Rathmann | M | - | - | |
| Daniel J. Levitt | M | 76 | 8 years | |
| Earl Warren Brien | M | 64 | 5 years | |
| David A. Lowe | M | 77 | 2 years | |
| Benjamin S. Levin | M | 46 | 12 years | |
| Pitch Johnson | M | 95 | - | |
| Richard L. Wennekamp | M | 80 | - | |
| Michael Molkentin | M | 69 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 8 years |
| Gregory R. Liberman | M | 51 | - | |
| Marvin R. Selter | M | 95 | 11 years | |
| Rajesh Shrotriya | M | 79 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 4 years |
| W. Dorsey Stuart | M | - |
Cetus Corp.
| 2 years |
| Peter Farley | M | - |
Cetus Corp.
| 14 years |
| Behzad Khosrovi | M | 80 |
Cetus Corp.
| 14 years |
| Thomas J. White | M | 78 |
Cetus Corp.
| 11 years |
| Sanjeev Gurunath Redkar | M | 56 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 13 years |
| Douglas Scott Wieland | M | 64 | 12 years | |
| David J. Haen | M | 45 | - | |
| Joseph Connell | M | 67 | 1 years | |
| Audrey F. Jakubowski | M | 81 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 9 years |
| Charles Casamento | M | 78 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 9 years |
| Christopher A. Hadsall | M | 49 | - | |
| Shi-Chung Ng | M | 69 | - | |
| Shanta P. Chawla | M | 76 | 3 years | |
| Herbert H. McDade | M | 97 | - | |
| Olivia Ware | F | 67 | 1 years | |
| Kirk C. Peacock | M | 55 | 1 years | |
| Jaisim Shah | M | 63 | - | |
| Luigi Lenaz | M | 83 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 3 years |
| Robert Emanuele | M | 69 | 14 years | |
| Walter J. Lack | M | 76 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 11 years |
| Matthew Natalizio | M | 69 | 3 years | |
| Bill Bowes | M | 97 | - | |
| Robert Farrell | M | 74 | 2 years | |
| Thomas V. Girardi | M | 84 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 11 years |
| Raymond C. Carnahan | M | - | - | |
| Mark A. Tepper | M | 49 | - | |
| David Scott Geyer | M | 65 | - | |
| David L. Snitman | M | 72 | - | |
| Gordon Binder | M | 88 | 18 years | |
| Jack R. Barber | M | 68 | - | |
| Mitchell K. Fogelman | M | 72 | 1 years | |
| Larry Alan May | M | 74 | 15 years | |
| G. Kirk Raab | M | 88 | 4 years | |
| Daniel Vapnek | M | 85 | 15 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 61 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joseph Rubinfeld
- Personal Network
